StoxMax Healthcare Institute vs Glenmark Pharmaceuticals: share price & financials comparison
NSE: MAXHEALTH vs GLENMARK · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Max Healthcare Institute vs Glenmark Pharmaceuticals at a glance
Max Healthcare Institute (MAXHEALTH) has a market capitalisation of ₹90,907 Cr, against ₹73,095 Cr for Glenmark Pharmaceuticals (GLENMARK). Over the past year Glenmark Pharmaceuticals has returned +40.5%, compared with -21.5% for Max Healthcare Institute. On valuation, Max Healthcare Institute trades at a lower P/E of 65.8 versus 82.5. Max Healthcare Institute earns a higher return on equity (12.2% vs 7.9%). Max Healthcare Institute comes out ahead on size, profitability and growth. Glenmark Pharmaceuticals comes out ahead on valuation, financial health, momentum and technicals. Across the scored metrics below, Max Healthcare Institute leads on 8 and Glenmark Pharmaceuticals on 9. On StoxGud's 10-point checklist, Max Healthcare Institute scores 3/10 and Glenmark Pharmaceuticals scores 5/10.
| Metric | Max Healthcare Institute | Glenmark Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹90,907 Cr | ₹73,095 Cr |
| Revenue (latest FY) | ₹8,373 Cr | ₹16,983 Cr |
| Net profit (latest FY) | ₹1,442 Cr | ₹0 Cr |
| Valuation | ||
| P/E | 65.8 | 82.5 |
| P/B | 8.02 | 6.52 |
| Dividend yield | 0.16% | 0.19% |
| Profitability | ||
| Return on equity | 12.2% | 7.9% |
| Net profit margin | 15.1% | 5.6% |
| Operating margin | 26.8% | 20.3% |
| Growth | ||
| Revenue growth (YoY) | +20.3% | -31.3% |
| Net profit growth (YoY) | -15.5% | -100.0% |
| Revenue CAGR (multi-year) | +27.3% | +9.2% |
| Financial health | ||
| Debt to equity | 0.33 | 0.08 |
| Momentum | ||
| 1-month return | +2.9% | +13.5% |
| 1-year return | -21.5% | +40.5% |
| 3-year CAGR | +16.3% | +50.8% |
| 5-year CAGR | +22.5% | +37.6% |
| 10-year CAGR | — | +11.2% |
| Distance from 52W high | -20.9% | +0.0% |
| Technicals | ||
| RSI (14) | 79 | 79 |
| Price vs 200-day avg | -7.6% | +15.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Max Healthcare Institute | Glenmark Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 3/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Max Healthcare Institute or Glenmark Pharmaceuticals?
Max Healthcare Institute has a market cap of ₹90,907 Cr and Glenmark Pharmaceuticals has a market cap of ₹73,095 Cr as of 06 Nov 2026.
Which has a lower P/E, Max Healthcare Institute or Glenmark Pharmaceuticals?
Max Healthcare Institute has the lower P/E: Max Healthcare Institute trades at 65.8 and Glenmark Pharmaceuticals at 82.5.
Which gave better returns in the last year, Max Healthcare Institute or Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals did better: Max Healthcare Institute returned -21.5% and Glenmark Pharmaceuticals returned +40.5% over one year.
Is Max Healthcare Institute or Glenmark Pharmaceuticals a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Max Healthcare Institute scores 3/10 and Glenmark Pharmaceuticals scores 5/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.